Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Схожие документы

• E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
  по: Claudiani, Simone, et al.
  Опубликовано: (2017)
• MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
  по: Claudiani, Simone, et al.
  Опубликовано: (2019)
• Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
  по: Ibrahim, Amr R., et al.
  Опубликовано: (2011)
• The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
  по: Khorashad, Jamshid Sorouri, et al.
  Опубликовано: (2009)
• Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
  по: Claudiani, Simone, et al.
  Опубликовано: (2020)